Why Your Class IIa Active Device Still Needs Expert Panel Review

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The answer lies in a classification rule that many teams miss during their initial risk classification exercise. Rule 13.

Rule 13 does not classify devices. It triggers additional scrutiny. It operates independently from the classification rules that determine your device class. This separation creates confusion in regulatory departments and delays in certification timelines.

Let me show you how this works in practice and why it matters for your clinical evaluation strategy.

What Rule 13 Actually Does

Rule 13 is not about determining class. It identifies active devices intended to administer or remove medicinal products.

The wording in Annex VIII is specific: “All active devices intended to administer and/or remove a medicinal product are classified as class IIa.”

But then comes the critical part: Devices specifically intended to be used in combination with a medicinal product must undergo a conformity assessment with the involvement of a Notified Body in respect of the conformity of the device with Article 54 requirements.

This is the mechanism. Your device might already be Class IIa under Rule 10. Or Class I under Rule 1. Rule 13 does not change that classification. It adds a layer of review.

When Article 54 Review Becomes Mandatory

Article 54 governs the consultation mechanism with the Expert Panel on medical devices. The Notified Body must refer your technical documentation to the Expert Panel before issuing a certificate if your device falls under certain conditions.

For active devices, the condition is clear: devices that incorporate a medicinal substance or are specifically intended for use in combination with a medicinal product.

Now, here is where regulatory strategy matters.

If your device administers medication but is not specifically intended for use with a particular medicinal product, Rule 13 still applies. But Article 54 review may not be triggered. The distinction is subtle but real.

I have seen nebulizers sail through without Expert Panel review. I have seen insulin pumps go to the Panel. The difference was in the intended purpose statement and the specificity of the medicinal product integration.

What “Specifically Intended” Means in Practice

Notified Bodies interpret this based on your technical file. If your instructions for use name a specific drug, you cross into Article 54 territory. If your device is described as compatible with a class of medications but not tied to a specific one, you may avoid the Panel review.

This is not about gaming the system. This is about accurate intended purpose definition from the start. If your device truly functions independently of a specific medicinal product, say so clearly. If it does not, do not pretend otherwise to avoid review.

The Expert Panel will see through vague intended purpose statements. So will the Notified Body during assessment. And if you modify your intended purpose later to avoid scrutiny, you create a documentation trail that raises red flags during audits.

What the Expert Panel Actually Reviews

When your device goes to the Expert Panel, they do not review your entire technical documentation. They focus on the interface between the device and the medicinal product.

According to MDCG 2020-13, the Panel evaluates:

• The benefit-risk determination related to the device-drug combination
• Clinical data supporting safe and effective use with the medicinal product
• Labeling and instructions for use regarding the medicinal product interaction
• Risk management related to the drug administration or removal function

This is a focused review. But it is also a slow one.

The consultation process can add months to your certification timeline. The Panel meets at scheduled intervals. Your submission enters a queue. You receive questions. You respond. The Panel reconvenes. More questions may follow.

I worked on a combination device where the Expert Panel consultation extended the certification by eight months. Not because of major deficiencies. Because of the procedural rhythm of the Panel review process itself.

Preparing for Expert Panel Questions

The Panel will ask about clinical evidence specific to the device-drug interaction. They want to see that you evaluated risks related to drug dosing accuracy, contamination, medication degradation, and user error in the context of the specific medicinal product.

Your clinical evaluation report must address this. If your CER treats the device function generically without addressing the medicinal product interaction, you will receive deficiencies.

Your risk management file must include hazards related to incorrect drug delivery, over-dosing, under-dosing, cross-contamination, and compatibility issues. If your ISO 14971 risk analysis does not explicitly address these medicinal product-related risks, the Panel will notice.

Your usability evaluation under IEC 62366-1 must demonstrate that users can safely operate the device with the medicinal product. This means actual testing with representative users, the actual drug (or a validated surrogate), and realistic use conditions.

The Notified Body’s Role Before and After the Panel

Your Notified Body does not decide whether to consult the Expert Panel. MDR Article 54 makes this mandatory when the conditions apply. The Notified Body identifies whether your device meets those conditions, then initiates the consultation.

Before the consultation, the Notified Body conducts its own review. They assess your technical documentation for completeness. They evaluate your clinical evaluation. They verify your risk management file. Only when they consider your documentation sufficient do they forward it to the Panel.

This means you face two review layers. The Notified Body review, then the Panel review.

After the Panel issues its opinion, the Notified Body considers that opinion in its certification decision. The Panel’s opinion is not binding, but Notified Bodies take it seriously. If the Panel identifies concerns, the Notified Body will require you to address them before issuing a certificate.

I have not seen a Notified Body ignore a negative Panel opinion. I have seen manufacturers withdraw applications after receiving unfavorable Panel feedback. The practical reality is that the Panel’s view carries significant weight.

What Happens When the Panel Finds Issues

The Panel may conclude that your clinical data is insufficient. They may find that your risk mitigation measures are inadequate. They may question your benefit-risk determination.

When this happens, you must address their concerns through additional testing, additional clinical data, design modifications, or changes to labeling and intended use.

This can be expensive. It can delay market access by a year or more. It can require pivoting your regulatory strategy entirely.

But here is the other side of that reality.

When the Panel finds issues, they are usually issues that post-market surveillance would have exposed anyway. Better to find them during assessment than after launch. Better to address them in the technical file than in field safety corrective actions.

Planning Your Regulatory Timeline

If Rule 13 applies to your device and Article 54 review will be triggered, build this into your project plan from the beginning.

Add six to twelve months to your certification timeline. Prepare your clinical evaluation with the Panel review in mind. Conduct usability testing early enough to incorporate findings before submission. Engage your Notified Body early to confirm their interpretation of Rule 13 applicability.

Some manufacturers try to avoid this delay by classifying their device differently. They argue that their device does not “administer” medication, it merely “delivers” it. They claim their device is not “specifically intended” for use with a medicinal product, even though their marketing materials describe exactly that.

These arguments rarely succeed. Notified Bodies and the Expert Panel look at the actual function and the actual use. They read your IFU. They examine your clinical data. They review your marketing claims. Inconsistencies become major non-conformities.

The Cost of Misclassification

If you classify your device to avoid Rule 13 and Article 54 review, and that classification is later challenged, you face serious consequences.

Your certificate can be suspended. Your devices may need to be recalled. You may need to restart the certification process under the correct classification. You lose time, money, and market credibility.

I worked with a manufacturer who launched a Class I device under Rule 1, arguing it was a simple accessory for medication administration. Post-market surveillance data showed the device was being used as an integral part of a chemotherapy delivery system. The competent authority reclassified it. The manufacturer had to withdraw from the market, conduct a full clinical evaluation, and apply for Class IIa certification with Article 54 review. Two years of market access lost.

This is not a theoretical risk. It happens.

Practical Steps for Active Device Manufacturers

First, review your classification worksheet. If your device administers or removes medicinal products, Rule 13 applies. Determine whether your device is specifically intended for use with a particular medicinal product. If yes, Article 54 review is mandatory.

Second, prepare your clinical evaluation to address the device-drug interaction explicitly. Include clinical data on dosing accuracy, compatibility, stability, and user error rates. Address risks specific to the medicinal product.

Third, conduct usability testing with the actual medicinal product or a validated surrogate. Document how users interact with the device in realistic medication administration scenarios. Identify use errors related to dosing, contamination, and handling.

Fourth, update your risk management file to include medicinal product-related hazards. Show how your design, labeling, and instructions mitigate these risks. Reference your usability data and clinical evidence.

Fifth, engage your Notified Body early. Confirm their interpretation of Rule 13 applicability. Ask about their experience with Expert Panel consultations for similar devices. Understand their submission requirements.

Sixth, build the Expert Panel consultation timeline into your project plan. Prepare for a six to twelve month extension of your certification process. Plan your product launch dates accordingly.

When Rule 13 Applies But Article 54 Does Not

There is a narrow space where Rule 13 triggers Class IIa classification but Article 54 review is not required. This happens when your device administers or removes medicinal products but is not specifically intended for use with a particular medicinal product.

In this case, you follow standard Class IIa certification procedures without Expert Panel consultation. Your Notified Body assesses your technical documentation. They review your clinical evaluation and risk management. They do not forward your file to the Expert Panel.

This distinction matters. It saves time and cost. But it requires clear documentation of your intended purpose and accurate reflection of your device’s actual function.

If you are in this situation, document it clearly in your classification rationale. Explain why your device is not specifically intended for use with a particular medicinal product. Provide evidence from your IFU, your marketing materials, and your clinical data. Show consistency across all documentation.

Your Notified Body will verify this. They will check for inconsistencies. They will look at how you describe your device in different contexts. If they find contradictions, they will escalate the file to the Expert Panel out of caution.

Clarity and consistency prevent this.

What Comes Next in This Series

This is the reality of Rule 13 and Expert Panel procedures for active devices. The regulatory framework is specific. The process is structured. The consequences of misclassification are serious.

But this is only one part of the Expert Panel landscape under MDR. In the next part of this series, I will address devices incorporating or derived from human tissues or cells. Rule 18 and Article 54 create a different set of review triggers with different evidence expectations.

Understanding these distinctions helps you plan your clinical evaluation and regulatory strategy from the beginning. It prevents delays. It prevents deficiencies. It prevents the expensive pivots that come from discovering regulatory requirements too late in the development process.

Until then, review your classification. Check your Rule 13 applicability. Prepare your clinical evidence for the specific review that your device will face.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.